Vanguard Group Increases Stake in Nektar Therapeutics to 4.98%

The Vanguard Group, Inc. has filed an amendment to its Schedule 13G, disclosing an increased ownership of 4.98% in Nektar Therapeutics. As of September 30, 2025, Vanguard holds 948,647 shares of Nektar's common stock, up from 729,492 shares previously. This represents a 30.04% increase in shares and a 226.77% increase in the value of the holdings, now valued at $61,595,649.71. The filing indicates that Vanguard's clients, including investment companies and managed accounts, have the right to receive dividends or proceeds from the sale of these securities. The amendment was signed by Ashley Grim, Head of Global Fund Administration, on October 31, 2025.